MRNA
Overvalued by 155.1% based on the discounted cash flow analysis.
Market cap | $50.85 Billion |
---|---|
Enterprise Value | $42.90 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-15.86 |
Beta | 1.17 |
Outstanding Shares | 383,239,726 |
Avg 30 Day Volume | 3,587,723 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -8.52 |
---|---|
PEG | 0.54 |
Price to Sales | 10.22 |
Price to Book Ratio | 4.03 |
Enterprise Value to Revenue | 8.33 |
Enterprise Value to EBIT | -8.35 |
Enterprise Value to Net Income | -8 |
Total Debt to Enterprise | 0.01 |
Debt to Equity | 0.04 |
No data
No data